November 3, 2026 · Nelson Marques, RD, CSSD
Tongkat Ali's Eurycomanone Number: Why '400 mg Tongkat Ali Extract' Can Mean Anywhere From 0.8% to 10% of the Compound That Matters
Tongkat ali labels compete on the front panel in milligrams of extract and nothing else. 200 mg. 400 mg. 600 mg. 1,200 mg. The number the clinical trials actually dosed — eurycomanone percentage — is almost never on the front and often not on the back either. A 400 mg capsule at an unspecified standardization can deliver anywhere from 3 mg to 40 mg of eurycomanone, a 13x range at the same front-label milligram. Here is what eurycomanone is, what the Physta and LJ100 standardization anchors mean, what the research actually dosed, and the 20-second Supplement Facts read that separates a serious tongkat ali product from a milligram-of-ground-root number.
Tongkat Ali's Eurycomanone Number: Why "400 mg Tongkat Ali Extract" Can Mean Anywhere From 0.8% to 10% of the Compound That Matters
The tongkat ali aisle in 2026 is where the ashwagandha aisle was in 2020. A wall of bottles, almost every one of them with a trademark symbol floating next to the word "extract," almost every one of them shouting a milligram number on the front — 200 mg, 400 mg, 600 mg, 1,200 mg, "4,000 mg equivalent" — and almost every one of them silent on the single number that predicts whether the capsule does anything the clinical trial literature says tongkat ali does.
That number is the eurycomanone percentage. It is the quassinoid compound the Malaysian government's Forest Research Institute spent two decades characterizing as the primary bioactive in Eurycoma longifolia, the plant tongkat ali powder is extracted from. It is the compound the Ismail and Henkel and Chen research groups dosed in the human trials on testosterone, cortisol, and perceived stress. It is the fraction that the two legitimate standardized extracts in the category — Physta and LJ100 — anchor their label commitments to. And it is the number that disappears entirely from the generic "tongkat ali extract 400 mg" bottle on the shelf next to them.
The gap is not small. A 400 mg generic tongkat ali capsule at an unspecified standardization can deliver anywhere from about 3 mg of eurycomanone (at a 0.8% background concentration, roughly what you get from re-bagged raw root powder) to about 40 mg of eurycomanone (at a 10% hot-water-extracted concentration standardized to the Physta spec). That is a 13x range of actual active-compound dose at an identical front-label milligram number. The buyer paying the same money for both is not buying the same supplement.
This post walks what eurycomanone is, the standardization anchors the category ships against, the 100-to-400 mg per-day trial-dose range the human literature actually sits inside, the forms problem (water-extracted vs ethanol-extracted vs raw-root powder sold as "extract"), and the 20-second Supplement Facts read that separates a serious tongkat ali product from a milligram-of-ground-root number.
What Eurycomanone Actually Is
Eurycoma longifolia is a slow-growing understory tree native to Southeast Asia. The root is the part the supplement industry uses, and it contains three principal bioactive compound classes — the quassinoids (dominated by eurycomanone and its structural analogs), the alkaloids (canthin-6-one and derivatives), and a class of long-chain peptides sometimes marketed as "eurypeptides" (a term the LJ100 patent holder coined for the proteolyzed peptide fraction of their specific extract process).
The quassinoids are the most mechanistically characterized class. Eurycomanone itself is a bitter, water-soluble, structurally complex molecule that has been studied for effects on steroidogenic enzyme expression (particularly aromatase inhibition in the testicular Leydig cell), cortisol metabolism, and androgen-receptor-pathway signaling. The majority of the peer-reviewed trial literature on tongkat ali for performance, hormonal, and stress-related endpoints uses extracts standardized to a specified eurycomanone percentage, with the dose typically expressed in milligrams of total extract containing a defined eurycomanone fraction.
The raw root of Eurycoma longifolia contains approximately 0.3% to 1.2% eurycomanone by dry weight, depending on the age of the tree (older roots contain more), the growing region, and the processing conditions used to dry and mill the root before extraction. That is the baseline. Anything called an "extract" should concentrate from that baseline. The question the Supplement Facts panel has to answer is: concentrate to what?
The Physta and LJ100 Standardization Anchors
Two patented standardized extracts dominate the clinical-trial literature on tongkat ali, and understanding them is the fastest way to read the generic category.
Physta. A hot-water-extracted standardized tongkat ali manufactured by Biotropics Malaysia from the Malaysian Forest Research Institute's cultivar program. Standardized to a defined profile that includes approximately 22% glyco-saponins, 30% polysaccharides, 40% proteins, and a eurycomanone content that typically runs 0.8% to 1.5% depending on the production batch. The Chen 2014 strength and body-composition trial in men used 400 mg/day of Physta for twelve weeks. The Talbott 2013 cortisol-and-perceived-stress trial used 200 mg/day for four weeks. The Henkel 2014 testosterone-and-muscle-strength trial in seniors used 400 mg/day for five weeks. The Physta label commitment is to the whole-extract profile rather than a single-compound eurycomanone percentage, which is a legitimate standardization approach for a water-extracted product where the clinical literature was built on the whole-extract spec rather than an isolated-fraction spec.
LJ100. A proprietary tongkat ali extract from HP Ingredients standardized to 22% eurypeptides (the proteolyzed peptide fraction) and approximately 40% glyco-saponins. The Ismail 2012 and Tambi 2012 testosterone and late-onset-hypogonadism trials used 200 mg/day of LJ100. Eurycomanone itself in LJ100 runs approximately 1.4% to 2.0% depending on batch. Like Physta, the label commitment is to a defined multi-component standardization profile rather than a single-compound figure.
Generic "100:1 tongkat ali extract." This is the shelf category that dominates the price-leader segment and where the standardization question gets murky. A "100:1" claim theoretically means 100 kilograms of raw root concentrated into 1 kilogram of extract, which should produce a eurycomanone concentration in the 5% to 10% range if the extraction captured the quassinoid fraction cleanly. In practice, "100:1" has no legal standardization meaning in the US supplement market, and the actual eurycomanone content in generic 100:1 products ranges from under 1% to over 10% across the independent verifications that academic groups and consumer-testing labs have published. The front label shows "400 mg tongkat ali 100:1 extract." The back label almost never shows the eurycomanone percentage. The buyer has no way to know what dose of the compound the trials used is actually in the capsule.
Raw-root powder sold as "extract." The lowest-rung category. A product that reads "tongkat ali root extract 1,200 mg" on the front but lists no standardization and no concentration ratio, and whose Supplement Facts panel reads only "Tongkat Ali (Eurycoma longifolia) Root ... 1,200 mg." The 1,200 mg is almost certainly ground raw root at the native 0.3% to 1.2% eurycomanone baseline, delivering 4 to 14 mg of eurycomanone from the whole capsule — within the lower end of the trial range by accident, but across a huge batch-to-batch variability that the label does not control.
The Trial-Anchored Dose Range
The human clinical trial literature on tongkat ali, after you filter down to the trials that used a standardized extract and reported hard endpoints on hormone status, perceived stress, cortisol-to-testosterone ratio, or body composition, concentrates in a 100 to 400 mg/day range of standardized extract across study durations of two to twelve weeks. The specific eurycomanone dose implied by that range depends on which standardization anchor:
- At the Physta 0.8% to 1.5% eurycomanone spec, the 200 to 400 mg trial dose delivers roughly 1.6 to 6 mg of eurycomanone per day.
- At the LJ100 1.4% to 2.0% eurycomanone spec, the 200 to 300 mg trial dose delivers roughly 2.8 to 6 mg of eurycomanone per day.
- At a higher-concentration 5% to 10% eurycomanone extract (less common in the trial literature but increasingly available on the retail shelf), 100 to 200 mg of total extract would land in the same 5 to 20 mg eurycomanone range.
The practical dose range the trial literature supports is roughly 2 to 20 mg of eurycomanone per day, with most of the published trials landing between 2 and 10 mg. That is the number the retail label has to let you calculate. A 400 mg capsule at a disclosed 2% eurycomanone standardization delivers 8 mg. A 400 mg capsule at a disclosed 10% eurycomanone standardization delivers 40 mg. A 400 mg capsule at an undisclosed standardization delivers something between 3 mg and 40 mg depending on which batch of which supplier's generic 100:1 is in the bottle this quarter.
The dose-response curve above 20 mg of eurycomanone per day is not well characterized in the human literature. Several of the newer high-concentration-extract products on the market deliver 50 to 100 mg of eurycomanone per capsule, pushing well above the studied range. There is not strong evidence that higher doses produce proportionally larger effects, and there is some concern that the quassinoid class has a dose-dependent hepatic signal at chronic high intakes that the Southeast Asian regulatory literature has flagged, though no clean dose-toxicity threshold has been established in humans at the chronic use levels the retail category sells.
The Hot-Water vs Ethanol Extraction Problem
The extraction solvent used to produce the tongkat ali extract matters because the different compound classes have different solubility profiles.
Hot-water extraction (the Physta and LJ100 process) captures the water-soluble glyco-saponin and polysaccharide fractions, the eurypeptide fraction, and the eurycomanone quassinoid cleanly. It leaves behind the lipid-soluble alkaloid fraction, which is partly a safety feature — the canthin-6-one alkaloids are the compounds that carry most of the historical bitterness and most of the hepatic-signal concern from older uncharacterized Southeast Asian traditional preparations. Water-extracted products reproducibly land the clinically trialed profile and are the extraction method most of the human research sits inside.
Ethanol or methanol extraction captures a different profile, concentrating the lipid-soluble alkaloid fraction alongside the quassinoids and producing an extract with a different bioactive mix than the trial literature validated. Some generic 100:1 products use ethanol extraction because it gives a higher total-weight yield and a higher visual-marker eurycomanone percentage on paper. Whether the ethanol-extracted profile reproduces the water-extracted clinical effects is not established, and the alkaloid-content shift raises the hepatic-signal question in a way the water-extracted profile does not.
"Full-spectrum" or "whole-root" products. A marketing category more than a technical one. In practice, these are often simply raw root powder with a higher dose number on the label. The lack of concentration means the eurycomanone content tracks the native 0.3% to 1.2% raw-root baseline and the per-capsule active dose sits at the low end of the trial range even with a large milligram claim.
The label the buyer wants is one that discloses the extraction solvent (water-extracted is the default clinical standard), the standardization target (eurycomanone percentage or the branded Physta / LJ100 spec), and the per-serving milligrams of total extract that implies a specific per-serving milligram of eurycomanone. Any product that discloses two of those three lets you calculate the third. A product that discloses none of them is selling you ground root powder with a trademark symbol next to it.
The Multi-Ingredient Blend Problem
Tongkat ali shows up most frequently in multi-ingredient "men's hormone support" or "testosterone support" formulas rather than as a standalone capsule, and the formula structure is where the eurycomanone dose question gets buried further. The typical T-support formula declares a 1,500 mg to 2,500 mg proprietary blend that includes tongkat ali alongside fenugreek, ashwagandha, zinc, vitamin D, boron, maca, horny goat weed, D-aspartic acid, and sometimes DIM or ginger. (For the broader proprietary-blend problem on these panels, see proprietary blends are where underdosing hides.)
With no per-ingredient disclosure, the buyer cannot determine whether the tongkat ali content inside the 1,800 mg blend is 400 mg of a Physta-grade standardized extract (a trial-anchored dose) or 50 mg of generic ground root powder (a decorative ingredient at a fifth of the trial range). The blend format rewards the formulator who includes ingredients at marketing-grade sub-clinical doses because the per-ingredient disclosure that would reveal the gap is not required. The multi-ingredient T-support category is where the tongkat ali underdose problem compounds most reliably with the ashwagandha underdose, the fenugreek underdose, and the DAA underdose. All four can sit inside the same blend at a fraction of the trial dose, and all four count on the Supplement Facts line.
The clean exception, when it exists, discloses each ingredient at a defined dose and standardization — "Physta tongkat ali extract (standardized to the Biotropics 22% glyco-saponin / 40% polysaccharide / 40% protein / 1.2% eurycomanone profile) ... 400 mg" alongside "KSM-66 ashwagandha extract (standardized to 5% withanolides) ... 600 mg" and so on. If you can read the specific standardization and the specific milligram beside each ingredient, the formula is doing the work. If you cannot, assume the dose is marketing-grade.
The 20-Second Supplement Facts Read
Four questions. (For the general version of this read, see how to read a supplement label in 60 seconds.)
-
Is there a standardization specification on the back label? The front "400 mg tongkat ali extract" is not a standardization. The back has to say either a specific eurycomanone percentage (ideally 1.5% to 10% depending on the extract class), a specific branded standardization anchor (Physta, LJ100), or a defined multi-component profile with eurycomanone named. "Standardized" without a number is not a standardization.
-
Does the per-serving math produce a eurycomanone dose inside the 2-to-20 mg range? Multiply the per-serving extract milligrams by the standardization percentage. 400 mg × 2% eurycomanone = 8 mg eurycomanone — inside the range. 400 mg × 0.5% = 2 mg — at the floor. 200 mg of unspecified "100:1" — unknowable, and that is the problem.
-
Is the extraction solvent disclosed, and is it water? Water-extracted (hot-water-extracted, aqueous-extracted) is the profile the trial literature was built on. Ethanol-extracted is a different compound mix. An undisclosed solvent on a generic 100:1 is a flag.
-
Standalone capsule or multi-ingredient proprietary blend? A standalone tongkat ali capsule with a disclosed per-serving milligram and standardization is the format the trial literature translates to. A proprietary blend that declares "Men's Hormone Support Blend 1,800 mg (containing: tongkat ali extract, fenugreek extract, ashwagandha root, zinc, boron, D-aspartic acid, maca root)" is a format that hides the per-ingredient dose and should be assumed to deliver a marketing-grade sub-clinical quantity of each ingredient until proven otherwise by per-ingredient disclosure.
Twenty seconds, four questions, no bottle survives all four questions without actually being standardized. The product that cannot answer any of them is the one the generic shelf is selling, and the per-serving eurycomanone dose it delivers is unknowable from the label — which is a different problem than being low, and worse for the buyer, because the batch-to-batch variability of an unspecified extract means two bottles of the same product can deliver meaningfully different amounts of the compound the trials actually dosed.
The milligram number on the front of a tongkat ali bottle is the first thing the buyer sees. It is also the last thing the clinical-trial literature cares about. The number that matters is downstream of it, and most of the category has designed the label to let you miss that.
SUBSCRIBE
Get more like this.
Evidence-based writing on supplements, performance nutrition, and the research behind what actually works. No spam, no daily emails — just the good stuff.
